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Abstract
Rationale: The clinical features of patients infected with pulmonary
nontuberculous mycobacteria (PNTM) are well described, but the
genetic components of infection susceptibility are not.
Objectives: To examine genetic variants in patients with PNTM,
their unaffected family members, and a control group.
Methods:Whole-exome sequencing was done on 69 white patients
with PNTM and 18 of their white unaffected family members. We
performed a candidate gene analysis using immune, cystic fibrosis
transmembrance conductance regulator (CFTR), cilia, and
connective tissue gene sets. The numbers of patients, family
members, and control subjects with variants in each category were
compared, as was the average number of variants per person.
Measurements andMain Results: A significantly higher number
of patients with PNTM than the other subjects had low-frequency,
protein-affecting variants in immune, CFTR, cilia, and connective
tissue categories (35, 26, 90, and 90%, respectively). Patients with
PNTMalsohad significantlymore cilia and connective tissue variants
per person than did control subjects (2.47 and 2.55 compared with
1.38 and 1.40, respectively; P = 1.43 1026 and P = 2.73 1028,
respectively). Patients with PNTM had an average of 5.26 variants
across all categories (1.98 in control subjects; P = 2.83 10217), and
they were more likely than control subjects to have variants in
multiple categories. We observed similar results for family members
without PNTM infection, with the exception of the immune category.
Conclusions: Patients with PNTM have more low-frequency,
protein-affecting variants in immune, CFTR, cilia, and connective
tissue genes than their unaffected family members and control
subjects. We propose that PNTM infection is a multigenic disease in
which combinations of variants across gene categories, plus
environmental exposures, increase susceptibility to the infection.
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nontuberculous mycobacteria
Nontuberculous mycobacteria (NTM) are
ubiquitous in the environment but rarely
cause clinical disease. Disseminated
nontuberculous mycobacterial infections
occur only in the setting of immune
compromise, such as genetic or acquired
defects of the IFN-g–IL-12 pathway.
Isolated pulmonary nontuberculous
mycobacterial (PNTM) infections, by
contrast, are associated with disorders of
mucociliary clearance, such as cystic
fibrosis (CF) or primary ciliary dyskinesia
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(PCD). PNTM infections also occur in
a distinct group of patients in whom there is
no apparent underlying cause. These
patients tend to be tall and lean white
women who are diagnosed with PNTM
infection in their sixth decade of life (1).
They were found to have higher rates of
scoliosis, pectus excavatum (PE), mitral
valve prolapse (MVP), and mutations in
the cystic fibrosis transmembrance
conductance regulator (CFTR) gene than did
matched control subjects in the National
Health and Nutrition Examination Survey
(1). Additionally, these patients may have
a significantly decreased ciliary beat
frequency compared with healthy control
subjects (2). These clinical features, as well as
the presence of familial clustering of disease
(3), suggest that genetic factors play a role
in susceptibility to PNTM disease. To
further investigate the genetics of PNTM
susceptibility, we performed whole-exome
sequencing on 69 white patients with
PNTM and 18 of their family members
without PNTM infection and compared
these data with sequencing data of the
appropriate 1000 Genomes Project (1000G)
control subjects. Some of the results of
these studies have been reported previously
in the form of conference abstracts (4, 5).
Methods
A detailed description of the methods can be
found in the Materials and Methods section
of the online supplement.
Cohort and Sample Collection
Patients were recruited from 2001 to 2013
at the National Institutes of Health (NIH)
Clinical Center, Bethesda, MD. All patients
and their family members provided
informed consent under institutional
review board–approved NIH protocols. All
patients with PNTM had microbiologic
and radiographic evidence of PNTM
infection according to the American
Thoracic Society criteria for PNTM disease
(6). Patients and their family members
were also evaluated for evidence of
bronchiectasis, scoliosis, PE, MVP, joint
hypermobility, the Steinberg thumb sign,
and the Walker-Murdock wrist sign (7).
DNA was isolated from blood collected
from patients with PNTM and their family
members seen at the NIH and from saliva
(catalog number OG-500, Oragene; DNA
Genotek, Ottawa, ON, Canada) of family
members who did not travel to the NIH
for evaluation. Because of the intrafamilial
consistency and the relative reads on the
sequences, we believe that the variants
reported here reflect germline changes
and not somatic ones. Lists of patients and
pedigrees are provided in Table E1 and
Figure E1, respectively, in the online
supplement.
Sequencing and Variant Filtering
Whole-exome sequencing was performed
on collected samples, and Illumina
sequencing assay reads (Illumina, San
Diego, CA) were aligned with Burrows-
Wheeler Aligner (8). Single-nucleotide
variants (SNVs) and insertions and
deletions (indels) were called with GATK
(9) and annotated by using SnpEff,
ANNOVAR, and CADD (10–12). The
sequencing data are publicly available in the
database of genomes and phenotypes
known as dbGaP (accession number
phs000719.v1.p1).
Principal components analysis (PCA)
was performed with smartpca in
EIGENSTRAT 4.2 (13) using one PNTM-
affected proband from each family and
from the sporadic cases.
Exome data were filtered for variants
present in patients with PNTM (PNTM-
associated variants) in VarSifter (14) using
a custom query with three parameters: gene
name, population frequency less than 2%,
and variant consequence (nonsynonymous,
splicing, stop-gain, stop-loss, and start-loss
variants). The genes examined were in
immune, connective tissue, and cilia
pathways, as well as CFTR (Table E2).
Sequencing files from 1000G were filtered
with the same parameters to obtain an
overall set of variants not specifically
associated with PNTM infection (“PNTM-
unassociated variants”). The filtered
PNTM-associated variants and PNTM-
unassociated variants are outlined in Tables
E3 and E4, respectively.
The indel dataset was filtered by gene
name and impact factor (“moderate” or
“high”). Filtered indels are given in Table E5.
Targeted Sanger sequencing was done
for variants interesting to the authors. For that
sequencing, custom primers for the relevant
genes were used (Table E3). Primer sequences
are available upon request. We observed
a false-positive rate of 0% (n = 0 of 39).
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At a Glance Commentary
Scientific Knowledge on the
Subject: Patients who have
pulmonary nontuberculous
mycobacterial (PNTM) infection with
no apparent underlying cause are
known to be mostly postmenopausal
white women who have a distinct body
morphotype, high rates of cystic
fibrosis transmembrance conductance
regulator (CFTR) heterozygosity, and
decreased ciliary beat frequency.
However, the genetic underpinnings of
these features and the susceptibility to
PNTM infection are not understood.
What This Study Adds to the
Field: Patients with PNTM have
a burden of immune, CFTR, cilia, and
connective tissue gene variants higher
than that of control subjects, and they
are more likely to have variants in
multiple gene categories. This suggests
that susceptibility to PNTM infection
is multigenic, resulting from a
combination of variations in genetic
categories that mirror the phenotype
of the patient.
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Statistical Analysis
Statistical testing was performed in R (15).
The number of samples with variants was
compared with a two-tailed Fisher’s exact
test. The average numbers of variants per
person were compared by unpaired two-
tailed t testing with Welch’s correction.
P values of 0.05 or less were considered
statistically significant.
A C-a burden test was performed
on the quality-controlled SNV dataset




We performed whole-exome sequencing on
102 individuals (20 patients with PNTM,
25 unaffected family members spread across
12 families, and 57 patients with sporadic
PNTM infection). After quality control,
three PNTM-affected samples and two
PNTM-unaffected relatives’ samples were
removed. To determine the appropriate
control population based on the genetic
ancestry of the PNTM infection cohort,
PCA was performed on the remaining
family probands and sporadic cases. Two
families and one sporadic case were
grouped with the CHB (Han Chinese in
Beijing, China) and JPT (Japanese in
Tokyo, Japan) East Asian populations, and
the other nine families and sporadic cases
were grouped with the CEU (Utah
Residents with Northern and Western
European Ancestry) and TSI (Toscani in
Italia) European populations (Figure 1). We
continued analysis with only the European
samples (15 patients with PNTM, 18
unaffected family members spread across 9
families, and 54 patients with sporadic
PNTM infection) (Figure 2A). Features
associated with PNTM disease, such as
bronchiectasis or scoliosis (1), were present
in some family members without PNTM
infection. The 1000G Phase I European
samples were used as controls. This control
dataset is composed of 53% women and
47% men, with no available age or
phenotype information.
Gene Filtering
Our initial approach to gene discovery was
to look for variants that tracked with PNTM
disease in each of the families and then to
check for their presence in sporadic cases.
This approach was limited by family
structures that were not conducive to
effective variant filtering, and we did not
identify any obvious candidate variants.
Next, we performed burden testing across
the whole exome in plinkseq, which also did
not yield any specific unifying genes.
Therefore, we pursued a broad candidate
gene approach using the previously
identified gene sets as recognized through
the study of well-characterized diseases (e.g.,
CF, PCD, inherited immune disorders, and
inherited disorders of connective tissue).
Using the final breakdown into PNTM-
affected, PNTM-unaffected, and 1000G
control groups (Figure 2B), we present
a gene set analysis in each of these four
genetic domains (i.e., immune, CFTR, cilia,
and connective tissue). We also discuss
variants found in each category that seemed
particularly intriguing, details on which can
be found in the online supplement.
Immune Genes
The genes involved in the synthesis of and






































Figure 1. Principal components analysis of patients with pulmonary nontuberculous mycobacterial (PNTM) infection. (A) The majority of patients with
PNTM group with the 1000 Genomes TSI (Toscani in Italia) and CEU (Utah residents with Northern and Western European Ancestry) European
populations. (B) Three samples (circled in A and B) group with CHB (Han Chinese in Beijing, China) and JPT (Japanese in Tokyo, Japan) populations,
indicating that they are of Asian descent. Those patients and their family members were excluded from further analysis. Also note that, though several
patients with PNTM self-identified as Hispanic, none group with the MEX (Mexican ancestry from Los Angeles, CA) population. PC1 and PC2 = principal
components 1 and 2; PNTM_proband = one patient with PNTM infection from each family; PNTM_sporadic = patients with sporadic PNTM infection.
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control of mycobacteria, as clearly
exemplified by Mendelian defects in these
genes in cases of disseminated bacillus
Calmette-Guérin and NTM infections,
sometimes referred to as “Mendelian
susceptibility to mycobacterial disease”
(MSMD) (16). Because these genes are so
clearly implicated in mycobacterial
susceptibility outside the lung, we explored
them in the setting of isolated lung NTM
disease. For the immune gene set, we
included the 10 genes often considered part
of MSMD (IFNGR1, IFNGR2, IL12RB1,
IL12B, STAT1, IKBKG, CYBB, ISG15, IRF8,
and GATA2). We also included other genes
that might have an overlap with MSMD
genes in terms of convergent pathways or
reported phenocopies (RAG1, RAG2,
IL12A, IL12RB2, MPEG1, CARD9, and
CLEC4D). Interrogation of these 17 genes
in our cohort identified 19 PNTM-
associated variants that passed the filters
(Table E3). None of the previously
recognized MSMD mutations were
identified; the heterozygous changes seen
in STAT1, IRF8, CARD9, CLEC4D, and
MPEG1 have not previously been
associated with disseminated NTM. Thirty-
five percent of patients with PNTM had
variants in one of these immune pathway
genes, significantly more than the 11%
observed in the control population and 6%
observed in the unaffected family members
(P = 2.53 1026 and P = 0.02, respectively)
(Table 1). Those who had variants typically
only had one, regardless of sample group
(Table 1).
We found the following variants of
particular interest. Signal transducer and
activator of transcription 1 (STAT1)
c.796G.A; p.V266I, heterozygous in two
unrelated patients with PNTM infection,
is a reported gain-of-function mutation
originally described in an immune
dysregulation–polyendocrinopathy–
enteropathy, X-linked–like syndrome (17).
IRF8 c.287C.T, p.T96M, heterozygous in

















































100% (69) 28% (5) ND
% with scoliosis, 
MVP, PE, and/or 
hypermobility (n)
72% (50) 61% (11) ND
B
Figure 2. The structure and characteristics of the pulmonary nontuberculous mycobacterial (PNTM) infection whole-exome cohort. (A) A schematic
depiction of how the original dataset was winnowed down to the samples used for analysis in this study. (B) The final breakdown of patients with PNTM
infection, their unaffected family members, and 1000 Genomes Project (1000G) control samples used in candidate gene set analysis, including sex, age,
incidence of bronchiectasis, and proportion with at least one connective tissue feature. In this case, connective tissue features included scoliosis, mitral
valve prolapse (MVP), pectus excavatum (PE), and joint hypermobility. ND = not determined; QC = quality control.
Table 1. Immune Gene Results
Immune Variants PNTM Affected (n) PNTM Unaffected (n) 1000G Control (n)
Samples with at least one PNTM-associated variant 24 1 41
Samples without a PNTM-associated variant* 45 17 338
Average number of variants per person† 1.17 1.00 1.07
Definition of abbreviations: 1000G = 1000 Genomes Project; ND = not done, because there were too few samples in the unaffected family members of
patients with pulmonary nontuberculous mycobacterial infection; PNTM= pulmonary nontuberculous mycobacterial infection.
*PNTM affected versus PNTM unaffected, P = 0.02; PNTM unaffected versus 1000G control, not significant (P. 0.05); PNTM affected versus 1000G
control, P = 2.53 1026.
†PNTM affected versus PNTM unaffected, ND; PNTM unaffected versus 1000G control, ND; PNTM affected versus 1000G control, not significant (P. 0.05).
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the DNA binding domain of the protein,
similar to the other mutations reported in
this gene (18). Preliminary results show
that introduction of this mutation into
mouse bone marrow derived macrophages
decreased the expression of Irf8 target genes
compared with wild-type protein (E. P.
Szymanski and S. Togi, unpublished
results). Three patients with PNTM had
heterozygous changes in macrophage-
expressed gene 1, perforin-2 (MPEG1):
c.217A.G, p.T73A; c.946C.T, p.P316S;
c.1192C.T, and p.Q398X. MPEG1 changes
have not previously been reported in
humans, but preliminary functional studies
of these patients’ cells showed decreased
killing of intracellular Mycobacterium
avium (R. McCormack, unpublished
results). Six patients with PNTM, including
a sibling pair, had heterozygous variants in
caspase recruitment domain family 9
(CARD9): c.143411G.C (splice variant),
E249K, R315H, and V385L. CARD9
biallelic loss-of-function mutations lead
to Candida meningitis, chronic
mucocutaneous candidiasis, and other
disseminated fungal infections (19–23). The
C-type lectin receptors that signal through
CARD9 recognize mycobacteria in addition
to fungi, and pulmonary mycobacterial
disease in Card92/2 mice cannot be
controlled (24, 25). There are no reports of
the clinical effects of heterozygous CARD9
mutations in humans, but Card91/2 mice
show a modest increase in susceptibility
to fungal infection (R. Drummond and
M. Lionakis, unpublished results).
The lung is a major point of entry for
environmental NTM infection, where even
a slight defect in mycobacterial handling
might permit persistence of mycobacteria
and other organisms. Therefore, late-onset,
milder clinical disease localized to the lung
may be more likely to be associated with
apparently mild heterozygous changes in
immune response genes. These immune
variants that we have identified in patients
with PNTM and not their family members
are distinct from the known MSMD
mutations.
CFTR Variants
Cystic fibrosis is a critical paradigm for
understanding PNTM disease. PNTM
infection is associated with bronchiectasis; it
is limited to the lung; and its incidence
increases with age (26, 27). Previous studies
have identified increased rates of
heterozygous CFTR variants in patients
with PNTM disease (1, 28). Therefore, we
examined CFTR variants in our patients
with PNTM and their unaffected family
members. Sixteen CFTR PNTM-associated
variants passed our filters (Table E3) and
were found in 23% of patients with PNTM
infection and 44% of unaffected family
members, with the prevalence in both
groups being significantly different from
the 6% prevalence observed in control
subjects (P = 2.83 1025 and P = 1.13
1025, respectively) (Table 2). Two CFTR
deletions were also noted in two additional
patients with PNTM, for an overall CFTR
variation rate of 26% in patients with
PNTM (Table E5). This percentage would
increase to 32% if we included four
additional patients with PNTM who had
intronic CFTR variants that may contribute
to PNTM disease (see online supplement).
All 18 changes were subsequently classified
by the mutation report in the CFTR2
database (The Clinical and Functional
Translation of CFTR [CFTR2]; available at
http://cftr2.org): 6% are known to cause CF
(n = 1); 44% are parts of complex alleles but
do not cause CF on their own (n = 8); 17%
are associated with elevated sweat chloride
and may cause CFTR dysfunction (n = 3);
6% are associated with normal sweat
chloride and do not cause CFTR
dysfunction (n = 1); and 28% are rare
variants of unknown effect (n = 5). Of the
26 members of the total PNTM cohort
(i.e., patients with PNTM and their
unaffected family members) with changes
in CFTR, 69% had just one change (either
variant or indel) in CFTR (n = 18) and 31%
had two changes (n = 8). Of note, the only
two unaffected family members with two
changes in CFTR had bronchiectasis with
no infection. The average number of CFTR
variants per person was not significantly
different relative to that of control subjects
(Table 2). Of the 18 patients with PNTM
with a CFTR change, 17 had at least one
variant in another candidate gene category.
Cilia Genes
An increasing number of genes are
recognized to control cilia formation,
structure, and function. We filtered for the
30 genes that have been clearly implicated in
human PCD (29), plus an additional 10
genes with roles in ciliogenesis or ciliary
beat frequency; 105 PNTM-associated
variants passed those filters (Table E3). We
identified cilia-related gene variants in 90% of
patients with PNTM, significantly more than
45% in control subjects (P = 4.33 10213)
(Table 3). Patients with PNTM had an
average of 2.47 cilia variants per patient,
significantly more than the 1.38 cilia
variants per control subject (P = 1.43 1026,
Table 3). The number of unaffected family
members with cilia variants was not
significantly different from control subjects,
but the average number of variants per
person was significantly higher than that of
control subjects (2.63) (Table 3). Four
deletions—in GAS2L2, DNAH5, and RPGR—
also passed our filters, but they were
not included in the statistical analysis
(Table E5).
We found the following variants of
particular interest. Two siblings with PNTM
Table 2. CFTR Results
CFTR Variants PNTM Affected (n) PNTM Unaffected (n) 1000G Control (n)
Samples with at least one PNTM-associated variant 16 8 22
Samples without a PNTM-associated variant* 53 10 357
Average number of variants per person† 1.19 1.25 1.32
Definition of abbreviations: 1000G = 1000 Genomes Project; CFTR = cystic fibrosis transmembrance conductance regulator; PNTM= pulmonary
nontuberculous mycobacterial infection.
*PNTM affected versus PNTM unaffected, not significant (P. 0.05); PNTM unaffected versus 1000G control, P = 1.13 1025; PNTM affected versus
1000G control, P = 2.83 1025.
†All comparisons, not significant (P. 0.05).
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infection had homozygous splice mutations
in radial spoke head 1 homolog (RSPH1)
that caused mild PCD (30). Each of three
patients with PNTM had different
heterozygous variants in macrophage-
stimulating 1 receptor (MST1R), which is
not known to be a disease-causing gene, but
has been implicated in bronchiectasis and
ciliary beat frequency (31, 32).
Connective Tissue Genes
Connective tissue features have long been
recognized as part of the clinical phenotype
of PNTM disease, sometimes eponymized as
“Lady Windermere syndrome” (33). These
features include tallness, leanness, scoliosis,
pectus abnormalities, and MVP, all of
which occur at increased rates compared
with both general and demographically
similar control populations (1, 34, 35).
Therefore, we included 24 connective tissue
genes in our survey; 99 PNTM-associated
variants passed our filters (Table E3).
Ninety percent of patients with PNTM had
at least one of these variants, significantly
more than the 57% frequency in control
subjects (P = 3.03 1028) (Table 4). Patients
with PNTM had an average of 2.55
connective tissue variants per patient,
significantly more than the 1.40 connective
tissue variants per control subject (P =
2.73 1028) (Table 4). This significance
held also when we compared connective
tissue variants in patients without PNTM
with those of control subjects (Table 4). Of
interest, 78% of unaffected family members
had bronchiectasis, scoliosis, MVP, PE,
and/or joint hypermobility, all features that
may be influenced by the wide variation in
connective tissue genes within this group.
Three indels also passed our filters,
although they were not included in our
statistical comparison. Each of three
patients with PNTM had apparently
deleterious indels in FBN2, TGFBR1, and
SMAD6 (Table E5).
We found the following variants of
particular interest. One patient with PNTM
infection had heterozygous FBN2 c.2260G.A,
p.G754S, a variant that likely causes
congenital contractural arachnodactyly
(36), as well as heterozygous COL5A1
(collagen type V, alpha 1) c.1588G.A,
p.G530S mutation, which causes mild
Ehlers-Danlos syndrome (EDS) in the
homozygous state (37–39). The latter
mutation was found in 12% of the PNTM
infection cohort compared with 4% in
European 1000G control subjects and with
other reported control frequencies of 2–6%
(37–39). Six patients with PNTM with the
G530S mutation had bronchiectasis and
four had scoliosis, joint hypermobility, and/
or the wrist and thumb signs. Of the five
unaffected family members with the G530S
mutation, four had scoliosis, PE, or wrist
and thumb signs. The G530S mutation is
known to be associated with mild collagen
defects and could possibly affect body
morphotype and lung structure and healing
in this PNTM infection cohort (37–39).
Multiple Categories
Table 5 summarizes the findings of this
candidate gene set approach. More patients
with PNTM had at least two cilia or
connective tissue variants than did control
subjects (P = 4.43 10216 and P = 6.33
10214, respectively). This significance held
true, but to a lesser extent, when we
compared unaffected family members with
control subjects.
Patients with PNTM and their
unaffected family members had strikingly
more variants in any category per person
than did control subjects (5.26, 4.7, and 1.98
variants, respectively; P = 2.83 10217)
(Table 5). When we separated those
variants by category, a significantly higher
number of patients with PNTM and their
unaffected family members had one, two,
or three category “hits,” where a hit was
defined as one or more variants in the
Table 3. Cilia Gene Results
Cilia Variants PNTM Affected (n) PNTM Unaffected (n) 1000G Control (n)
Samples with at least one PNTM-associated variant 62 11 170
Samples without a PNTM-associated variant* 7 7 209
Average number of variants per person† 2.47 2.63 1.38
Definition of abbreviations: 1000G = 1000 Genomes Project; PNTM= pulmonary nontuberculous mycobacterial infection.
*PNTM affected versus PNTM unaffected, P = 0.007; PNTM unaffected versus 1000G control, not significant (P. 0.05); PNTM affected versus 1000G
control, P = 4.33 10213.
†PNTM affected versus PNTM unaffected, not significant (P. 0.05); PNTM unaffected versus 1000G control, P = 0.03; PNTM affected versus 1000G
control, P = 1.43 1026.
Table 4. Connective Tissue Gene Results
Connective Tissue Variants PNTM Affected (n) PNTM Unaffected (n) 1000G Control (n)
Samples with at least one PNTM-associated variant 62 18 214
Samples without a PNTM-associated variant* 7 0 165
Average number of variants per person† 2.55 2.5 1.40
Definition of abbreviations: 1000G = 1000 Genomes Project; PNTM= pulmonary nontuberculous mycobacterial infection.
*PNTM affected versus PNTM unaffected, not significant (P. 0.05); PNTM unaffected versus 1000G control, P = 7.93 1025; PNTM affected versus
1000G control, P = 3.03 1028.
†PNTM affected versus PNTM unaffected, not significant (P. 0.05); PNTM unaffected versus 1000G control, P = 0.0008; PNTM affected versus 1000G
control, P = 2.73 1028.
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immune or CFTR categories but two or
more variants in cilia or connective tissue
genes (Table 5). Two or more variants were
used for cilia and connective tissue because
of the higher burden of variants per person
in those categories (Tables 3–5). The
number of variants in each category is
summarized by sample in Table E6. The
number of genes in which SNVs and
indels were found for each category are
summarized in Figures 3A and 3B,
respectively.
plinkseq Burden Test
Because we had resorted to candidate gene
assessment, we wanted to explore whether
there were any overlooked or unrecognized
genes or pathways that might help explain
PNTMdisease. Therefore, we applied a broad
exome-wide search using plinkseq to assess
genetic burden using an unbiased approach.
The C-a test was used because it performs
well when there is a mixture of protective
and detrimental variants in the dataset.
With this test, 89 unique genes reached
significance (Table E7). The list was assessed
for gene function and pathways in Ingenuity
Pathway Analysis (IPA; QIAGEN, Redwood
City, CA), some of which were consistent
with our candidate gene categories (Table E8).
We also noted genes involved in lipid or
estrogen pathways, possibly relevant to the
typically tall, slender body habitus and female
predominance of patients with PNTM. Fifty-
three percent of burden genes fell under one
or more candidate categories, and the other
47% were in other noncandidate categories
(Table 6). Interestingly, one of the genes
significant by burden testing is SCNN1B,
which codes for the b-subunit of ENaC,
a gene implicated in nonclassical CF (40). The
only probable pathogenic variant in this gene
(c.245C.G, p.S82C) was identified in
PNTM-affected patient CJF_38.
Discussion
Mendelian genetics has transformed our
understanding of disease and the approach
to medicine itself. Whereas genetic
techniques have proven highly effective
in rare diseases with clear patterns of
inheritance and high penetrance, the genetic
dissection of common or complex disease
has been, as expected, much more difficult.
By their very nature, common, complex
diseases are likely to be a summation of
multiple genetic and environmental
influences. This is likely to be especially true
in diseases that are late in onset, which
thereby allows many environmental,
degenerative, or somatic mutational events
to occur. The disease under study here
presents in the fifth to sixth decade of life;
has sex, morphologic, and strong geographic
associations (41); and is associated with
pulmonary mycobacterial and other
infections. These characteristics make it
a particularly compelling example of these
multiple confounding features. Therefore,
despite the presence of familial clusters, it
seems most likely that the genetic basis of
PNTM disease is complex and the result of
multiple convergent pathways’ leading to
full phenotypic disease expression.
Given the distinct and widely reported
phenotypes associated with PNTM
infection, a combinatorial genetic approach
to studying PNTM disease seemed
reasonable to pursue. Compared with
1000G control subjects, more patients with
PNTM and their unaffected family members
had low frequency, protein-affecting






[n (%)] P Value*
Number of people with variants in each category
Immune
0 immune variants 45 (65%) 17 (94%) 338 (89%)
1 immune variant 21 (30%) 1 (6%) 38 (10%)
>2 immune variants 3 (4%) 0 (0%) 3 (1%)
CFTR
0 CFTR variants 53 (77%) 10 (56%) 357 (94%)
1 CFTR variant 13 (19%) 6 (33%) 16 (4%)
>2 CFTR variants 3 (4%) 2 (11%) 6 (2%)
Cilia
0 cilia variants 7 (10%) 7 (39%) 209 (55%)
1 cilia variant 22 (32%) 3 (17%) 121 (32%)
>2 cilia variants 40 (58%) 8 (44%) 49 (13%)
Connective Tissue
0 connective tissue variants 7 (10%) 0 (0%) 165 (44%)
1 connective tissue variant 17 (25%) 3 (17%) 142 (37%)
>2 connective tissue variants 45 (65%) 15 (83%) 72 (19%)
Variants in all candidate genes
Average number of variants per person† 5.26 4.7 1.98
Number of people with variants
At least 1 hit 63 (91%) 17 (94%) 156 (41%) 2.23 10215
At least 2 hits 44 (64%) 12 (67%) 28 (7%) 2.73 10224
At least 3 hits 17 (25%) 3 (17%) 0 (0%) 2.43 10215
4 hits 1 (1%) 0 (0%) 0 (0%) NS
Definition of abbreviations: 1000G = 1000 Genomes Project; CFTR = cystic fibrosis transmembrance conductance regulator; NS = not significant
(P. 0.05); PNTM= pulmonary nontuberculous mycobacterial infection.
*P values were derived by using Fisher’s exact test to compare the number of patients with PNTM with the number of 1000G control subjects.
†PNTM affected versus PNTM unaffected, NS; PNTM unaffected versus 1000G control, P= 0.0001; PNTM affected versus 1000G control, P = 2.83 10217.
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variants across all categories, as well as more
variants per person. However, the variants
in the immune category genes were almost
exclusively limited to the patients with
PNTM infection, suggesting that these
variants may be critical distinguishing
factors between patients and their
unaffected relatives. However, 23 of 24
patients with PNTM who had an immune
variant had variants in at least one other
category, implying that these immune
changes alone are not sufficient to cause
PNTM disease. Overall, members of the
PNTM infection cohort were more likely to
have variants in multiple candidate
categories. This observation still held true
when we specifically considered patients in
whom we identified Mendelian disease
variants (i.e., STAT1 gain of function,
RSPH1 causing PCD, COL5A1 causing mild
EDS, and CFTR changes). Multiple family
members affected by PNTM shared specific
variants in a few other instances (Table E3);
however, there was not sufficient evidence
for causality in those cases. Further familial
genetic studies may provide more power
for analysis, provided the study is carefully
designed to account for the nuances of
familial PNTM disease.
A parallel analysis of PNTM
infection–unassociated variants showed
extremely similar results (data not shown).
This method included filtered variants that
were found in the control dataset, but not
in the PNTM infection dataset, providing
additional assurance that our categorical
findings are valid.
Because there is always a risk of bias in
candidate searches, we undertook an
unbiased, exome-wide C-a burden test
in plinkseq, which identified a high
proportion of the gene categories we had
previously selected. Similarly, in a recent
study of the molecular basis of asthma,
investigators identified immunity- and
cilia-related categories in microarray gene
expression data (42). Both of these findings
offer further support to the relevance of the
categories we chose. As a whole, our
categorical data provide genetic evidence to
support the “susceptible persons” model of
PNTM infection (43, 44), whereby an
increased burden of variants in candidate
categories conspire to alter patients’ skeletal
structure, epithelial function, mucociliary
clearance, and local immune function, thus
enabling infection.
Digenic inheritance (alterations in
two different genes within the same pathway
combining to cause clinical disease)
has been described in many disorders,
including familial hemophagocytic
lymphohistiocytosis, retinitis pigmentosa,
Hirschsprung disease, and facioscapulohumeral
muscular dystrophy (45, 46). The model
of polygenic disease that we suggest for























































Figure 3. Number of genes in which variants or indels were found for each category. (A) The number
of genes in which a single nucleotide variant (SNV) was found for each category. Nine genes of 17
were found in the immune category, 1 of 1 in cystic fibrosis transmembrance conductance regulator
(CFTR), 29 of 40 in cilia, and 23 of 28 in connective tissue. (B) The number of genes in which an indel
was found for each category. None of 17 genes were found in the immune category, 1 of 1 for CFTR,
3 of 40 for cilia, and 3 of 28 for connective tissue. Dark gray bar areas indicate the number of genes
with a variant or indel, and the entire bar for each category indicates the total number of genes tested.
Table 6. Significant Genes from the C-a Burden Test by Candidate Category








Multiple candidate categories* 13 (15%)
Total candidate categories 47 (53%)
All significant burden genes 89
*Genes that were categorized in multiple categories (i.e., immune, respiratory, connective tissue, lipid,
and/or estrogen).
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the next logical level (Figure 4). We
hypothesize that variants in a handful of
different genes within a few relevant
pathways collude to cause PNTM disease.
The variants alone are not enough to cause
clinical disease, but together they make
disease more likely. On top of these complex
genetic factors, the clear influence of
environmental factors such as high water
vapor pressure and geographic variation in
exposure to NTM (47) illustrates the multiple
ways in which susceptible people can be
further affected by a conducive environment
(Figure 3). The late onset of PNTM disease
allows ample time for genetic, environmental,
and other factors to accumulate.
We found it difficult to pinpoint
a single, specific genetic basis of PNTM
infection. Patients with PNTM and their
family members shared a higher burden of
variants in several categories, except
immune genes. This overlap is not entirely
surprising, as 75% of PNTM infection
family members in our cohort had at least
one body characteristic associated with
PNTM disease, which is reflected in a larger
study of families affected by PNTM
infection (3). Because of these similarities,
there is the chance that unaffected family
members have not developed PNTM
disease yet. We have tried to minimize this
possibility by including unaffected family
members of similar ages to the patients
with PNTM (Figure 2B). The genetic
burdens we report in CFTR, ciliary
function, and connective tissue may be
associated more with susceptibility to
bronchiectasis than with PNTM infection
itself: 35% of family members of patients
with PNTM had bronchiectasis without
PNTM infection. Given that immune
variants were almost exclusively found
in patients with PNTM, these immune
genes might be critical discriminating
genetic factors for PNTM disease. The
involvement of immune function in PNTM
infection susceptibility is reiterated by the
associations of oral prednisone, anti–TNF-a
therapy, other immunomodulatory drugs,
AIDS, and MSMD with NTM infection (43,
44, 48, 49). Interestingly, the variants in
immune genes we identified (STAT1, IRF8,
MPEG1, and CARD9) are not MSMD-type
mutations and do not appear to be
associated with NTM disease outside the
lung. Finally, although we recruited patients
on the basis of NTM isolation, the vast
majority had concomitant pulmonary fungal
and bacterial infections, making the
underlying infectious driver hard to discern.
Therefore, it may be best to regard these
genetic associations as being characterized
by, but not limited to, NTM infection.
We are aware that our study is
only moderately sized and used 1000G
reference data for the control exomes.
Still, this is the largest whole-exome
database of patients with PNTM to date.
There are undoubtedly other pathways to
be identified that are relevant to this disease.
This study is also important for what we
did not find: The majority of the genes
relevant in MSMD were not identified,
confirming that the factors underlying
disseminated and pulmonary disease
segregate at the genetic level as they do
clinically. These findings may provide
insight into the ongoing quest to
understand this complex but relatively
common disease. n
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